Multiple organizations have recognized that postmenopausal women who experience a fragility fracture be tested for osteoporosis with a BMD test or treated for osteoporosis (The International Society for Clinical Densitometry 2015; National Osteoporosis Foundation 2014; North American Menopause Society 2010; US Department of Health and Human Services 2004). Pharmacologic treatment can reduce the risk of subsequent fractures by 30%–50%. Unfortunately, testing and treatment for low bone mass after fracture has been shown to be as low as 20%.
To help meet Healthcare Effectiveness Data and Information Set (HEDIS) measure, which require a BMD test or treatment, a letter was sent to both patients and physicians after hip fracture at the Cleveland Clinic (main campus). In 2019,166 hip fractures were admitted and treated. 100% of patients and primary care physicians were sent letters reviewing the need for evaluation and treatment and offering follow-up appointments if needed for evaluation.